

A practical guide for providers: 5 steps to help your ADHD patients find Azstarys in stock, plus alternatives and workflow tips.
When your ADHD patients are stable on Azstarys, the last thing anyone wants is a disruption in their treatment because they can't fill a prescription. But in 2026, that's exactly what many patients are facing.
Azstarys (Serdexmethylphenidate/Dexmethylphenidate) is not in a formal FDA-listed shortage, yet real-world availability remains spotty. As a prescriber, you're in a unique position to help your patients navigate these challenges. This guide covers the current availability situation, why patients are struggling, five concrete steps you can take, alternative options, and workflow tips to make the process smoother.
Azstarys is manufactured exclusively by Corium (a Sun Pharmaceutical company). No generic exists as of early 2026. The medication is available in three capsule strengths:
While Azstarys is not on the FDA shortage list, availability varies significantly by region and pharmacy type. Chain pharmacies frequently report out-of-stock status, while independent and specialty pharmacies may have more consistent supply.
Understanding the root causes helps you counsel patients and plan proactively:
Use Medfinder for Providers to check which pharmacies near your patient's location currently have Azstarys in stock. Then send the e-prescription to a pharmacy you've confirmed has it. This one step can prevent days or weeks of patient frustration.
Identify 2-3 pharmacies in your area that reliably carry Azstarys. Independent pharmacies and mental health specialty pharmacies are good candidates. Having a short list of "go-to" pharmacies for Azstarys saves time for your team and your patients.
Some pharmacies will stock Azstarys more consistently if they know they'll receive a steady stream of prescriptions from your practice. A brief call to the pharmacy manager to establish this relationship can go a long way.
Don't wait for the pharmacy to notify you about a PA denial. If you know the patient's insurance requires prior authorization for Azstarys, submit it when you write the prescription — or even before. Many electronic health records (EHRs) and e-prescribing platforms support real-time benefit checks that can flag PA requirements upfront.
Having the PA approved before the patient arrives at the pharmacy eliminates one of the most common reasons for fill failures.
If a patient's prescribed strength is unavailable, consider whether an alternative strength could work. For example, if 52.3 mg/10.4 mg is out of stock, could the patient temporarily use 39.2 mg/7.8 mg? This isn't ideal long-term, but it can prevent treatment interruptions.
Document the clinical rationale for the dose change and schedule a follow-up to reassess once the preferred strength is available.
Share these resources with your patients:
When Azstarys cannot be sourced, having a pre-discussed backup plan with your patient minimizes treatment gaps. The most clinically appropriate alternatives include:
For a detailed comparison, see our alternatives to Azstarys guide or the provider shortage briefing.
Integrating availability awareness into your prescribing workflow can dramatically improve patient outcomes:
Helping your patients find Azstarys in 2026 requires a proactive approach. By checking availability before prescribing, building pharmacy relationships, streamlining prior authorizations, and equipping patients with the right tools, you can significantly reduce treatment disruptions.
The supply situation isn't perfect, but it's manageable with the right workflow. Your patients are relying on you — and tools like Medfinder for Providers make it easier to deliver.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.